Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Diagnostic and therapeutic challenges

Authors

  • Nirali N. Shah,

    Corresponding author
    1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 1W-3750, 9000 Rockville Pike, Bethesda, MD 20892-1104
    Search for more papers by this author
  • Ulrike Bacher,

    1. Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Germany
    Search for more papers by this author
  • Terry Fry,

    1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Katherine R. Calvo,

    1. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Maryalice Stetler-Stevenson,

    1. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Diane C. Arthur,

    1. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Roger Kurlander,

    1. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Kristin Baird,

    1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Barbara Wise,

    1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Sergio Giralt,

    1. Department of Stem Cell Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center, New York City, New York
    Search for more papers by this author
  • Michael Bishop,

    1. Department of Stem Cell Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin
    2. Experimental Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Nancy M. Hardy,

    1. Experimental Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author
  • Alan S. Wayne

    1. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    2. Experimental Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    Search for more papers by this author

  • A physician or group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary

  • Conflict of interest: Nothing to report.

    A physician or group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary

    The National Cancer Institute (NCI) International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) was organized to identify, prioritize, and coordinate research activities related to the biology, natural history, prevention, and treatment of relapse after alloHSCT [1, 2]. As a part of that effort, a multidisciplinary tumor board was established at the NCI to review cases and provide guidelines for the diagnosis and management of post-transplant relapse of hematologic malignancies. This report summarizes a review of post-transplant myelodysplastic syndrome conducted in November 2010 at the NCI, Bethesda, Maryland.

Ancillary